Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
215.77
-5.12 (-2.32%)
Aug 11, 2026, 4:00 PM EDT - Market closed
Axsome Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 319.85 | 322.93 | 315.35 | 386.19 | 200.84 | 86.47 |
Cash & Short-Term Investments | 319.85 | 322.93 | 315.35 | 386.19 | 200.84 | 86.47 |
Cash Growth | 5.56% | 2.40% | -18.34% | 92.29% | 132.26% | -52.97% |
Accounts Receivable | 277.46 | 224.46 | 142 | 94.82 | 37.7 | - |
Inventory | 37.88 | 27.94 | 15.73 | 15.14 | 4.32 | - |
Other Current Assets | 21.38 | 13.65 | 11.98 | 8.12 | 2.78 | 0.05 |
Total Current Assets | 656.57 | 588.99 | 485.06 | 504.26 | 245.64 | 86.52 |
Net Property, Plant & Equipment | 20.03 | 21.42 | 5.97 | 7.62 | 1.14 | 0.94 |
Other Intangible Assets | 37.36 | 40.52 | 46.89 | 53.29 | 59.66 | - |
Goodwill | 12.04 | 12.04 | 12.04 | 12.04 | 10.31 | - |
Other Long-Term Assets | 35.45 | 26.84 | 18.53 | 11.03 | 14.72 | 0.32 |
Total Assets | 761.45 | 689.81 | 568.5 | 588.24 | 331.48 | 87.79 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 78.97 | 65.54 | 72 | 40.68 | 38.61 | 13.15 |
Accrued Expenses | 299.63 | 232.85 | 147.99 | 90.5 | 51.63 | 9.3 |
Short-Term Debt | 70 | 70 | - | - | - | - |
Current Portion of Leases | 0.65 | 0.43 | 1.84 | 1.27 | 0.43 | 0.62 |
Other Current Liabilities | 11.2 | 10.01 | 8.29 | 6.41 | 5.9 | - |
Total Current Liabilities | 460.45 | 378.84 | 230.1 | 138.85 | 96.56 | 23.07 |
Long-Term Debt | 117.96 | 117.75 | 180.71 | 178.07 | 94.26 | 49.09 |
Long-Term Leases | 30.6 | 27.39 | 8.99 | 7.04 | - | - |
Other Long-Term Liabilities | 69.14 | 77.54 | 91.68 | 73.3 | 31.1 | - |
Total Long-Term Liabilities | 217.7 | 222.67 | 281.38 | 258.41 | 125.36 | 49.09 |
Total Liabilities | 678.14 | 601.51 | 511.48 | 397.26 | 221.92 | 72.15 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
Additional Paid-in Capital | 1,505 | 1,394 | 1,180 | 1,027 | 705.89 | 424.83 |
Retained Earnings | -1,422 | -1,306 | -1,123 | -835.57 | -596.33 | -409.2 |
Shareholders' Equity | 83.3 | 88.3 | 57.02 | 190.98 | 109.56 | 15.63 |
Total Liabilities & Equity | 761.45 | 689.81 | 568.5 | 588.24 | 331.48 | 87.79 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 219.21 | 215.57 | 191.53 | 186.37 | 94.68 | 49.71 |
Net Cash (Debt) | 100.64 | 107.37 | 123.82 | 199.82 | 106.16 | 36.76 |
Net Cash Growth | 14.73% | -13.29% | -38.04% | 88.23% | 188.77% | -72.51% |
Net Cash Per Share | 1.98 | 2.16 | 2.58 | 4.40 | 2.61 | 0.98 |
Book Value | 83.3 | 88.3 | 57.02 | 190.98 | 109.56 | 15.63 |
Book Value Per Share | 1.64 | 1.77 | 1.19 | 4.20 | 2.69 | 0.42 |
Tangible Book Value | 33.9 | 35.73 | -1.92 | 125.65 | 39.59 | 15.63 |
Tangible Book Value Per Share | 0.67 | 0.72 | -0.04 | 2.77 | 0.97 | 0.42 |